Sign In
Buy BDSX
$16.10
+0.660 (+4.27%)
At Close: Jun 03, 2026
Biodesix, Inc. (NASDAQ:BDSX) Receives Consensus Rating of “Moderate Buy” from Brokerages
04:03am, Saturday, 07'th Mar 2026
Biodesix, Inc. (NASDAQ: BDSX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six analysts that are currently covering the company, Marketbeat reports. One equities research
Wall Street Analysts Think Biodesix (BDSX) Could Surge 111.62%: Read This Before Placing a Bet
10:56am, Tuesday, 03'rd Mar 2026
The mean of analysts' price targets for Biodesix (BDSX) points to an 111.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analy
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
10:41am, Tuesday, 03'rd Mar 2026
Here is how Biodesix, Inc. (BDSX) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript
09:17pm, Thursday, 26'th Feb 2026
Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript
Biodesix, Inc. (BDSX) Reports Q4 Loss, Beats Revenue Estimates
06:16pm, Thursday, 26'th Feb 2026
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $1.2 per share a year ago.
Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights
04:01pm, Thursday, 26'th Feb 2026
Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-p
Biodesix to Participate in Upcoming Investor Conferences
06:00am, Tuesday, 24'th Feb 2026
LOUISVILLE, Colo., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team will participat
Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
06:00am, Thursday, 12'th Feb 2026
LOUISVILLE, Colo., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quar
Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Increases By 499.1%
01:40am, Wednesday, 28'th Jan 2026
Biodesix, Inc. (NASDAQ: BDSX - Get Free Report) saw a significant growth in short interest in January. As of January 15th, there was short interest totaling 483,591 shares, a growth of 499.1% from the
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)
06:00am, Monday, 12'th Jan 2026
Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025. LOU
CochLear (OTCMKTS:CHEOY) versus Biodesix (NASDAQ:BDSX) Head-To-Head Review
01:08am, Friday, 02'nd Jan 2026
CochLear (OTCMKTS:CHEOY - Get Free Report) and Biodesix (NASDAQ: BDSX - Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the s
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 325.67%: Here's is How to Trade
10:55am, Wednesday, 03'rd Dec 2025
The mean of analysts' price targets for Biodesix (BDSX) points to a 325.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
Biodesix to Present New Data at Two Major Upcoming Scientific Meetings
08:22am, Wednesday, 03'rd Dec 2025
Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new
Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates
11:58pm, Monday, 03'rd Nov 2025
Biodesix, Inc. (BDSX) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.6. This compares to a loss of $1.4 per share a year ago.
Biodesix, Inc. (BDSX) Q3 2025 Earnings Call Transcript
10:46pm, Monday, 03'rd Nov 2025
Biodesix, Inc. ( BDSX ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Scott Hutton - President, CEO & Director Robin Cowie - CFO, Secretary & Treasurer Conference Call Partic
